Cancer risk following long-term exposure to systemic immunomodulatory therapies in psoriasis patients is possible.
To assess a dose-response relationship between cumulative length of exposure to biologic therapy and risk of cancer.
I. Garcia - Doval, M.A. Descalzo, K.J. Mason, A.D. Cohen, A.D. Ormerod, F.J. Gómez - García, S. Cazzaniga, I. Feldhamer, H. Ali, E. Herrera - Acosta, C.E.M. Griffiths, R. Stern, L. Naldi, The Psonet Network